Kesimpta More Cost-Effective for RRMS & Following My Own (MS) Advice.

Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, reads a new analysis regarding the fact that in Canada, Kesimpta is more cost-effective than other DMTs for treating relapsing-remitting MS.

He also reads “My Wife Says I Should Follow My Own (MS) Advice” by Ed Tobias, from his column “The MS Wire”.
===================================
Are you interested in learning more about multiple sclerosis? If so, please visit:
https://multiplesclerosisnewstoday.com/
=====================================
To join in on conversations regarding multiple sclerosis, please visit:
https://multiplesclerosisnewstoday.com/forums/